Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223922 · ClinicalTrials.gov registry record · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
A NA study of Brain Metastases, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT03223922: Recruiting NA study of Brain Metastases, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT03223922 is a NA study of Brain Metastases that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 24 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03223922, a NA study of Brain Metastases, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Primary Outcome
Evaluate changes in cognition from baseline to 4 months following genu-sparing whole brain radiation therapy (GS-WBRT)
Conditions Studied
Interventions
- RADIATION whole brain radiation therapy
Study Locations (2)
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Maryland
- The SKCCC at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2030-12 |
| Phase | NA |
What NCT03223922 shows while recruiting
NCT03223922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which whole brain radiation therapy is the first listed.
NCT03223922 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03223922 about?
NCT03223922 is a clinical study titled "Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases". This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
What is the current status of trial NCT03223922?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2017-07-19. Estimated completion is 2030-12.
What conditions does trial NCT03223922 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT03223922?
The interventions under investigation include: whole brain radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT03223922?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03223922 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03223922's enrollment target sits among peer trials
24 48th of 67 higher than 20 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
REMASTer: REcurrent Brain Metastases After SRS Trial
RECRUITING · NA
-
Development of MRF for Characterization of Brain Tumors After Radiotherapy
RECRUITING · NA
-
MeDex: No Perioperative Dexamethasone in Brain Metastases
RECRUITING · NA
-
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- NCT03437005 · 24 participants · Phase 1
Alternation in the Human Microbiome With Commonly Used Topical Medications
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI